DMAC Stock Overview
A clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
DiaMedica Therapeutics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.05 |
52 Week High | US$4.45 |
52 Week Low | US$1.94 |
Beta | 1.73 |
11 Month Change | 7.02% |
3 Month Change | 10.11% |
1 Year Change | -28.07% |
33 Year Change | -28.90% |
5 Year Change | -34.41% |
Change since IPO | -90.87% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
May 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 12FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
Jul 06We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Jun 16We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
Jan 04DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
Nov 05DiaMedica: Undercovered Stroke Drug Company With Decent Data
Jun 13We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
May 01Could The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Ownership Structure Tell Us Something Useful?
Feb 13We're Not Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn
Jan 09DiaMedica Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Shareholder Returns
DMAC | US Biotechs | US Market | |
---|---|---|---|
7D | 33.8% | -0.3% | 0.3% |
1Y | -28.1% | 11.0% | 22.5% |
Return vs Industry: DMAC underperformed the US Biotechs industry which returned 10.7% over the past year.
Return vs Market: DMAC underperformed the US Market which returned 22.9% over the past year.
Price Volatility
DMAC volatility | |
---|---|
DMAC Average Weekly Movement | 13.5% |
Biotechs Industry Average Movement | 10.3% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DMAC's share price has been volatile over the past 3 months.
Volatility Over Time: DMAC's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 19 | Rick Pauls | www.diamedica.com |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases.
DiaMedica Therapeutics Inc. Fundamentals Summary
DMAC fundamental statistics | |
---|---|
Market cap | US$112.37m |
Earnings (TTM) | -US$19.26m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.0x
P/E RatioIs DMAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DMAC income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$19.26m |
Earnings | -US$19.26m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.51 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did DMAC perform over the long term?
See historical performance and comparison